UCB products give Actient a platform for growth in urology
This article was originally published in Scrip
Executive Summary
Actient Pharmaceuticals, a new speciality company formed last year in the US with funding from private equity firm GTCR, has established a platform for commercial growth by licensing and acquiring six marketed pharmaceutical products from the US subsidiary of Belgian firm UCB.